Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Tiotropium bromide Stories

2014-04-07 12:23:29

LISBON, Portugal, April 7, 2014 /PRNewswire/ -- Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application. Hovione have designed this inhaler to have just two operating components, thereby achieving...

2014-03-28 12:22:00

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/8gxjqj/investigation ) has announced the addition of the "Investigation Report on China's Tiotropium Bromide Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug...

2014-03-01 12:20:30

For U.S. Media Only RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat(®) inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Diego. Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication. The first results...

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...

2013-10-28 08:29:11

Phase 2 and Phase 3 data presented at the 2013 American College of Chest Physicians (ACCP) annual meeting RIDGEFIELD, Conn., Oct. 28, 2013 /PRNewswire/ -- Boehringer Ingelheim today presented the latest data for tiotropium in asthma at the 2013 American College of Chest Physicians (ACCP) annual meeting (CHEST 2013) in Chicago. The CHEST session "Tiotropium and Asthma" features a total of four oral presentations from Phase 2 and 3 studies of tiotropium delivered via the...

2013-10-24 16:27:17

Eleven presentations on investigational compounds and an approved product will be presented at the CHEST 2013 meeting RIDGEFIELD, Conn., Oct. 24, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced the upcoming presentation of data from 11 abstracts, including 6 oral presentations, across the company's respiratory portfolio at the 2013 American College of Chest Physicians (ACCP) annual meeting, CHEST 2013, taking place October 26 - 31 in Chicago. These data exemplify...

2013-10-08 23:24:44

Reportbuyer.com just published a new market research report: Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth. London (PRWEB) October 08, 2013 Summary GBI Research, a leading business intelligence provider, has released its latest research report “Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture...

2013-09-09 08:28:07

DORVAL, QC, Sept. 9, 2013 /CNW/ - Novartis announced new analyses of data for investigational QVA149 (indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed clinically significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus those comparators evaluated in the study(1,2).( )These data were part of 39...

2013-09-08 20:20:21

Results presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 RIDGEFIELD, Conn., Sept. 8, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the results of TIOSPIR(TM) (Tiotropium Safety and Performance in Respimat) (NCT01126437), one of the largest international chronic obstructive pulmonary disease (COPD) trials conducted to date, at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, Spain. The...

2013-08-28 08:24:53

LABA/LAMA Fixed-Dose Combinations Will Achieve Over 35 Percent of COPD Sales in 2022, According to Findings from Decision Resources BURLINGTON, Mass., Aug. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of a new drug class that will drive sales through 2022. Currently, the COPD...